Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 222

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 10
Chunk 222
---
     -  
     (16,532,716) 
     (16,532,716)
  
    Balances, December 31, 2024 
     29,762,671  
    $-  
    $31,239,895  
    $(30,596,858) 
    $643,037 
  
    Balances 
     29,762,671  
    $-  
    $31,239,895  
    $(30,596,858) 
    $643,037 

The
accompanying notes to the financial statements are an integral part of these statements.

F-5

Telomir
Pharmaceuticals, Inc.

statements
of cash flows

    2024  
    2023 

    Year
    Ended December 31, 

    2024  
    2023 
  
    Cash flows from Operating
    activities 

    Net loss 
    $(16,532,716) 
    $(13,071,864)
  
    Adjustments to reconcile
    net loss to net cash from operations 

    Stock-based compensation
    expense 
     6,867,276  
     - 
  
    Credit loss expense- loan
    due from related party 
     130,000  
     - 
  
    Loss on extinguishment
    of debt 
     -  
     7,486,767 
  
    Amortization of debt issuance
    costs 
     4,338,543  
     1,611,458 
  
    Change in operating assets
    and liabilities: 

    Trade accounts payable
    and accrued expenses 
     183,629  
     114,556 
  
    Prepaid
    expenses 
     (57,160) 
     (713)
  
    Net
    cash used in operating activities 
    $(5,070,428) 
    $(3,859,796)

    Cash Flows from Financing
    activities 

    Payment of deferred offering
    costs 
     -  
     (255,970)
  
    Payments under related
    party line of credit 
     (101,000) 
     - 
  
    Proceeds from (payments
    to) due to/from related party 
     (433,945) 
     1,663,